JP6553605B2 - 血管新生抑制活性を有するペプチド、及びそれを含む組成物 - Google Patents

血管新生抑制活性を有するペプチド、及びそれを含む組成物 Download PDF

Info

Publication number
JP6553605B2
JP6553605B2 JP2016533182A JP2016533182A JP6553605B2 JP 6553605 B2 JP6553605 B2 JP 6553605B2 JP 2016533182 A JP2016533182 A JP 2016533182A JP 2016533182 A JP2016533182 A JP 2016533182A JP 6553605 B2 JP6553605 B2 JP 6553605B2
Authority
JP
Japan
Prior art keywords
composition
pep1
peptide
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016533182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539121A5 (OSRAM
JP2016539121A (ja
Inventor
サン チェ キム
サン チェ キム
Original Assignee
ジェムバックス アンド カエル カンパニー，リミティド
ジェムバックス アンド カエル カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェムバックス アンド カエル カンパニー，リミティド, ジェムバックス アンド カエル カンパニー，リミティド filed Critical ジェムバックス アンド カエル カンパニー，リミティド
Publication of JP2016539121A publication Critical patent/JP2016539121A/ja
Publication of JP2016539121A5 publication Critical patent/JP2016539121A5/ja
Application granted granted Critical
Publication of JP6553605B2 publication Critical patent/JP6553605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2016533182A 2013-11-22 2014-11-21 血管新生抑制活性を有するペプチド、及びそれを含む組成物 Active JP6553605B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20130142897 2013-11-22
KR10-2013-0142897 2013-11-22
KR10-2014-0020605 2014-02-21
KR20140020605 2014-02-21
PCT/KR2014/011280 WO2015076621A1 (ko) 2013-11-22 2014-11-21 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물

Publications (3)

Publication Number Publication Date
JP2016539121A JP2016539121A (ja) 2016-12-15
JP2016539121A5 JP2016539121A5 (OSRAM) 2018-01-11
JP6553605B2 true JP6553605B2 (ja) 2019-07-31

Family

ID=53179816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533182A Active JP6553605B2 (ja) 2013-11-22 2014-11-21 血管新生抑制活性を有するペプチド、及びそれを含む組成物

Country Status (7)

Country Link
US (1) US10034922B2 (OSRAM)
EP (1) EP3072519B1 (OSRAM)
JP (1) JP6553605B2 (OSRAM)
KR (3) KR102359396B1 (OSRAM)
CN (1) CN105848667B (OSRAM)
ES (1) ES2818921T3 (OSRAM)
WO (1) WO2015076621A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101997756B1 (ko) 2012-05-11 2019-07-08 주식회사 젬백스앤카엘 패혈증 예방 또는 치료용 조성물
ES3046661T3 (en) 2012-05-11 2025-12-02 Gemvax & Kael Co Ltd Anti-inflammatory peptides and composition comprising the same
CN104822698B (zh) 2012-07-11 2018-08-10 珍白斯凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
BR112015030627A2 (pt) 2013-06-07 2017-07-25 Gemvax & Kael Co Ltd marcadores biológicos úteis na imunoterapia contra o câncer
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US10632349B2 (en) 2017-11-03 2020-04-28 Parsons Xtreme Golf, LLC Golf club heads and methods to manufacture golf club heads
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016137162A1 (ko) 2015-02-27 2016-09-01 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CA3049727C (en) * 2017-01-13 2022-10-04 Vasomune Therapeutics Inc. An agent for promoting angiogenesis and methods and uses thereof
CN108421050A (zh) * 2017-02-15 2018-08-21 闵晓洁 小分子rna干扰端粒酶逆转录酶质粒抑制视网膜、脉络膜新生血管新制剂
KR101998155B1 (ko) 2017-09-22 2019-07-10 (주)케어젠 혈관신생 억제용 펩타이드 및 이의 용도
US20220054583A1 (en) * 2018-09-11 2022-02-24 Anbition S.R.L. Peptides and medical uses thereof
KR102467670B1 (ko) * 2022-05-16 2022-11-17 줄리아 연구소 주식회사 Shc1 단백질 또는 항-shc1 항체를 포함하는 혈관신생성 질환의 예방, 치료 또는 개선용 약학적 조성물 및 건강기능식품 조성물
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물
CN121001732A (zh) * 2023-05-17 2025-11-21 珍白斯凯尔有限公司 包含gv1001的用于预防或治疗黄斑变性的组合物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001915B1 (ko) 1990-06-27 1993-03-20 포항종합제철 주식회사 저온 소결 압전요업재료 제조방법
CA2632790A1 (en) 1996-07-22 1998-01-29 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
UA74130C2 (uk) 1997-05-15 2005-11-15 Чугаі Сейяку Кабусікі Кайся ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ
AU748442B2 (en) 1997-07-01 2002-06-06 Cambia Vertebrate telomerase genes and proteins and uses thereof
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
CA2432932A1 (en) * 2001-02-16 2002-08-29 Mark A. Scialdone Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US6967211B2 (en) 2001-04-10 2005-11-22 Nippon Shinyaku Co. Ltd. Remedial agent for chronic articular rheumatism
JP4502580B2 (ja) 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用
US20030143228A1 (en) 2001-10-29 2003-07-31 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
EA007927B1 (ru) 2002-04-10 2007-02-27 Апплайд Резеч Системз Арс Холдинг Н. В. Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
KR20050020987A (ko) 2002-06-12 2005-03-04 바이오겐 아이덱 엠에이 인코포레이티드 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법
CA2530900A1 (en) 2003-06-25 2004-12-29 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
KR20050040517A (ko) 2003-10-29 2005-05-03 주식회사 오리엔트 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐
DK1530965T3 (da) 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP5273721B2 (ja) 2005-03-21 2013-08-28 ビカス セラピューティクス，エルエルシー 悪液質を緩和するための組成物および方法
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
EP1991560B1 (en) 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
KR101574630B1 (ko) 2006-07-24 2015-12-07 (주)앰브로시아 허혈성 질환의 완화 및 치료를 위한 약학 조성물 및 그를 전달하기 위한 방법
EP2076531B1 (en) * 2006-10-12 2011-11-23 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
KR20090103957A (ko) 2007-01-29 2009-10-01 주식회사 프로셀제약 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도
JP2010532484A (ja) 2007-06-29 2010-10-07 コレロジック システムズ，インコーポレイテッド 卵巣癌のための予測マーカー
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CL2008002782A1 (es) * 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
SI2310044T1 (sl) 2008-06-16 2017-03-31 Mediolanum Farmaceutici S.P.A. Proti-tumorska imunoterapija
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
KR20110060940A (ko) 2008-09-22 2011-06-08 닛신 파마 가부시키가이샤 항염증성 펩티드
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
JP5653214B2 (ja) 2009-05-20 2015-01-14 東レ株式会社 細胞膜透過性ペプチド
KR20110057049A (ko) 2009-11-23 2011-05-31 박의신 기능성 전립선염 치료제
KR20110062943A (ko) 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
US9657068B2 (en) 2010-02-16 2017-05-23 Ultimovacs As Telomerase polypeptide vaccine for treating cancer
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
KR101263212B1 (ko) 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101388372B1 (ko) 2010-06-11 2014-04-23 한국화학연구원 청각보호 작용을 하는 신규 화합물
KR101348284B1 (ko) 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20120121196A (ko) 2011-04-26 2012-11-05 주식회사 글루칸 관절염 치료제
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR101288053B1 (ko) 2011-07-04 2013-07-23 동국대학교 산학협력단 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물
KR101361445B1 (ko) 2011-12-26 2014-02-12 성균관대학교산학협력단 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물
KR101680164B1 (ko) 2012-02-10 2016-11-28 하쿠신코우세이카이재단 단구 증식제, 단구 증식용 배지, 단구의 제조방법, 수지상 세포의 제조방법, 및 수지상 세포 백신의 제조방법
KR102041381B1 (ko) 2012-03-12 2019-11-27 젬백스 에이에스 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료
KR101997756B1 (ko) 2012-05-11 2019-07-08 주식회사 젬백스앤카엘 패혈증 예방 또는 치료용 조성물
ES3046661T3 (en) 2012-05-11 2025-12-02 Gemvax & Kael Co Ltd Anti-inflammatory peptides and composition comprising the same
CN104822698B (zh) 2012-07-11 2018-08-10 珍白斯凯尔有限公司 细胞穿透肽以及包含该肽的缀合物和组合物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
JP6510410B2 (ja) 2012-09-19 2019-05-08 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
EP4230644A3 (en) 2012-09-19 2024-04-24 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
BR112015030627A2 (pt) 2013-06-07 2017-07-25 Gemvax & Kael Co Ltd marcadores biológicos úteis na imunoterapia contra o câncer
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
WO2015182798A1 (ko) * 2014-05-28 2015-12-03 주식회사 카엘젬백스 골수-유래 억제세포(myeloid-derived suppressor cells, mdscs) 저해용 조성물
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016137162A1 (ko) 2015-02-27 2016-09-01 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
KR20170054310A (ko) 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법

Also Published As

Publication number Publication date
WO2015076621A1 (ko) 2015-05-28
KR102694658B1 (ko) 2024-08-14
US20160296604A1 (en) 2016-10-13
CN105848667B (zh) 2020-05-19
CN105848667A (zh) 2016-08-10
ES2818921T3 (es) 2021-04-14
EP3072519A1 (en) 2016-09-28
KR102494803B1 (ko) 2023-02-06
KR20220020411A (ko) 2022-02-18
KR102359396B1 (ko) 2022-02-08
KR20160079881A (ko) 2016-07-06
US10034922B2 (en) 2018-07-31
EP3072519B1 (en) 2020-08-19
KR20230020009A (ko) 2023-02-09
EP3072519A4 (en) 2017-04-19
JP2016539121A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
JP6553605B2 (ja) 血管新生抑制活性を有するペプチド、及びそれを含む組成物
US11026994B2 (en) Syndecan-2 compositions and methods of use
RU2683649C1 (ru) Композиция для лечения и профилактики доброкачественной гиперплазии простаты
US20180201651A1 (en) Pharmaceutical composition that is anticancer and suppresses cancer metastasis, containing, as active ingredient, fusion peptide simultaneously targeting cancer cell and tumor associated macrophage
AU2009201077A1 (en) Methods and compositions for modulating apoptosis
US10611798B2 (en) PAR1 and PAR2 c-tail peptides and peptide mimetics
JP2021510538A (ja) タンパク質性分子およびその使用
AU2022201911A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
EP3887390A1 (en) Dpep-1 binding agents and methods of use
WO2022234346A1 (en) Peptides targeting macrophages, and conjugates, compositions, and uses thereof
JP4991544B2 (ja) ストレス応答を媒介するためのペプチド阻害剤
KR102275912B1 (ko) Hsp 발현 억제 펩티드 및 이를 포함하는 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160818

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190704

R150 Certificate of patent or registration of utility model

Ref document number: 6553605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250